To characterize naringenin (NAR) population pharmacokinetics (PPK) in Chinese women with primary osteoporosis.
INTRODUCTION
Qianggu capsules, which we developed in 2003, have been widely used in China for the treatment of women with primary osteoporosis. Naringenin (4′ , 5, 7-trihydroxyflavanone, NAR), the active compound found in Qianggu capsules, has been reported to increase the bioavailability of other drugs, and have antioxidant, 1 anti-ulcer, 2 anti-tumor, anti-allergy, phlegm removing, cough suppressing, anti-inflammatory, and anti-hyperlipidemia activities. 3 Various methods have been reported for quantification of NAR in biological samples to support preclinical and clinical studies. Most reported approaches involve long and tedious sample detection and preparation, such as solid phase extraction or protein precipitation, which involves multiple steps. [3] [4] [5] Further, there is limited plasma data or pharmacokinetic parameters of NAR in humans. Inter-subject variability in pharmacokinetics can also vary considerably among individual drugs and depends on a variety of factors. One potential factor involves Traditional Chinese Medicine (TCM) symptoms. We aimed to use HPLC-MS/MS assay method to assess the sensitivity of NAR population pharmacokinetics to TCM symptoms.
MATERIALS AND METHODS
The following diagnostic criteria, inclusion criteria, exclusion criteria, exclusion criteria, subject recruitment, drug administration and blood sampling, chemicals and reagents, instrumentation, HPLC, analysis conditions, and sample preparation methods are based on previous reported methods with some minor modifications. 6 
Subject recruitment
Ninety-eight female subjects, aged 40 to 80 years, were recruited from the communities of Jiangshan, Beixinqiao, Jiaodaokou, Chaoyangmen, and Donghuamen in Beijing, China between September 2010 and April 2011. All subjects gave informed consent before participation, and the study was approved by Ethics Committee of Chinese Clinical Basic Institute, China Academy of Chinese Medical Sciences (Approval number: 2010No13).
Diagnostic criteria
The diagnostic criteria for osteoporosis were mainly obtained from Guideline of Clinical Diagnosis: Subvolume of Osteoporosis and Bone Mineral Salt Diseases (First edition). 1 Subjects whose T-score was less than or equal to -2.5 were considered to have osteopenia. 3 
Inclusion criteria
Patients were included if they volunteered to be a subject and signed an informed consent form. Those patients who were female, aged 40 to 80 years, and met the diagnostic criteria for osteoporosis were included.
Instrumentation
HPLC-MS/MS system (Agilent, Palo Alto, CA, USA) was used in this study. The HPLC-MS/MS system was comprised of a 6410 Triple Quadrapole mass spectrometer, and 1200 system was equipped with a 2170 binary system controller, a 1211 pump, a 1322-degasser, a 1329A auto-sampler, and a 1316A column oven. Data were collected and processed using Mass-Hunter software B 01.03 (Agilent, Palo Alto, CA, USA).
Drug administration and blood sampling
Blood samples of volunteers were taken after a single oral dosage of Qianggu capsules (Beijing Qi Huang Pharmaceutical Co., Ltd.). The principle drug in each dose was 250 mg of total flavonoid of Drynaria fortunei (Kunze) J. Sm., which contains 75 mg of NAR. 2 mL blood samples were collected from their median cubital vein and stored in 4 mL ethylene diamine tetraacetic acid microcentrifuge tubes immediately before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after oral administration. The samples were centrifuged at 10 000 ×g for 15 min at 4 ℃. A total of 500 μL of plasma were separated and kept frozen at − 80 ℃ until analysis. Blank plasma was purchased from the Red Cross Blood Center Warehouse of China and kept at a temperature of -40 ℃.
HPLC analysis conditions and sample preparation
An Agilent XDB C18 (50 mm × 4.6 mm, 1.8 μm) was used. The mobile phase was acidic water (containing 0.1% formic acid) (A) and acetonitrile (B) in the following gradient: 90% A → 30% A (0-4 min), 100% B (4.1 min), and 90% A (5.1 min) with a flow rate of 1.0 mL/min, separating ratio of 1:3, column oven temperature of 35 ℃ , and total run time of 3.0 min for each injection. The mass spectrometer was operated using electrospray ionization with an ionspray voltage of + 5500 V. Negative ion multiple-reaction-monitoring mode analysis was performed using nitrogen as the collision gas. The ionspray pressure was set at 40 psi, the flow rate of drying gas at 11 L/min, the drying gas temperature at 350 ℃, and precursor/product ion pairs for NAR and hesperidin at m/z 579.2/271.1 and m/z 609.3/301.0, respectively. With r2 equal to 0.9928, the linear relationship was statistically significant over the concentration range between 0.5 and 200 ng/L. The regression equation y = 0100089 + 41541x (y = peak area of NAR, x = concentration of NAR in plasma) was obtained by implementing the least-squares method. The limit of quantification was 0.5 ng/L based on a signal-to-noise ratio of 4∶1. A 0.2 mL aliquot of each plasma sample was transferred to 1.5 mL polypropylene tubes with 40 μL of internal standard, vortexed for 30 s, and then vortexed for another 2 min after 1 mL of ethyl acetate was added to the tube. After centrifugation (10 000 ×g), the supernatant was combined and transferred to another polypropylene tube and evaporated to dryness at room temperature under nitrogen gas. The final residue was dissolved in 100 μL of mobile phase, and the solution was injected into an HPLC system.
Base model selection
All data collected were subsequently processed by nonlinear mixed-effect modeling (NONMEM) software (NONMEM 7.1.2, PsN312112, CA, USA). Typical values of pharmacokinetic parameters of NAR were estimated using first-order post-hoc estimation. Parameters were assumed to follow the log-normal distribution across the population, and the residual error was characterized by a combined proportional and additive error model. All steps in the development of the pharmacokinetics model were executed based on the likelihood ratio test. An additional parameter was reserved if the resultant decrease in the objective function value (OFV) was > 3.84 (P < 0.05). One compartment model with first-order absorption and elimination was chosen, based on the known pharmacokinetic properties of NAR. The basic model was implemented in the subroutine ADVAN6 in NON-MEM, and the structural parameters to be estimated were clearance (C1), central distribution volume (V), absorption rate constant (Ka1), peripheral distribution volume (VII), and inter-compartmental clearance (CLII) The model frame is shown in Figure 1 . In the first step of the analysis, differential equations of the NAR base model were created as follows (equations 1-4):
These differential equations were then simplified based on the following assumption:
The differential equations were therefore set up as follows (equations 6-8):
(8)
Univariate analysis
The relationship between the Bayesian estimates and the main covariates were explored. Bodyweight, height, age, aspartate transaminase (AST), alanine transaminase (ALT), blood urea nitrogen (BUN), serum creatinine (Scr), and the symptom patterns, kidney-yang deficiency [Shenyangxu (SYAX)] and liver-kidney-yin deficiency [Ganshenyinxu (GSYI)], were tested in the univariate analysis. All covariates were tested one by one. A decrease of ≥ 3.84 in the OFV compared with the base model was selected as a statistically significant (P < 0.05) improvement of the fit of the model to the data.
Multiple regression analysis
Except for the weight of patients, TCM patterns were considered to be a possible covariate, which was added to the basic model using a forward selection procedure. All of the statistically significant covariates in the univariate analysis were entered into the full model. In the backward detection method, they were removed one at P.O.
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ka Naringenin Vc1 km Glocoside Vc2 kmo Naringenin (in vitro) Figure 1 Frame of the base model a time. The values of individual parameters for each subject from the basic model were plotted against these two covariates and graphically inspected for their relationships. Additional population models were examined with the progressive introduction of any covariates that were found to contribute to the statistically significant drop in OFV. A recursive backward elimination procedure was then performed to further refine the model, and a covariate was removed from the model if the increase of OFV was less than 10.84 (P < 0.001) during the exclusion. Two methods were applied for the creation of the full covariate model. In these methods, both forward and backward methods were used.
RESULTS

Baseline of subjects
Ninety-eight patients provided 253 data points for the population pharmacokinetics analysis. The time distribution scatter diagram is shown in Figure 2 . Summary demographic information of TCM patterns is provided in Table 1 , and other demographic information characteristics are shown in Figure 3 .
The points indicate that most detectable blood samples were collected between 0 min and 15 h. The y-axis indicates the concentration of naringenin in ng/μL.
Diagnostics and validation of the NAR base model
The main diagnostic plots for the base model are summarized in Figures 4 and 5, and the simulation results are shown in Figure 7 . Both the observed concentration data versus predicted concentration data of the population and individuals were scattered around the line of unity slope. Meanwhile, the weighted residuals were uniformly spread around the zero line, and the weighted residuals were normally distributed, which indicate that there was no bias in the base model. The results showed successful minimization, good correlation, and no large standard errors. It was found that one compartment base model with first-order ab-sorption and elimination best fit the concentration-time profiles of NAR following oral administration.
Creation of the NAR final model with forward method one
The covariate model of NAR was created using two methods. In method one, the forward method was conducted. The decrease in OFV in the forward method covariate model is shown in Table 2 . 
Creation of the NAR final model with backward method one
All of the statistically significant covariates during univariate analysis were entered into the full model. In the backward deletion step, only SYAX led to an increase in OFV > 6.63 (P < 0.01). The control stream of the backward analysis covariate model is shown in Table 3 . Figure 8 shows the main informal diagnostic plots for the final model by basic goodness-of-fit plots of observed concentrations versus population and individually predicted concentrations, weighted residuals versus observed concentration, and weighted residuals versus time.
Diagnostics of the NAR final model with method one
Both the observed concentration data versus predicted concentration data of population and individual were scattered around the line of unity slope. The weighted residuals were uniformly spread around the zero line, and the weighted residuals fell into a normal distribution, which demonstrated that there was no bias in the base model. 
Population parameters of the NAR final model with method one
The population parameters estimates of the final model with method one are listed in Table 4 .
Visual predictive checking of the NAR final model with method one
To assess the final model, the final model was checked by visual predictive checking, and the results are shown in Figure 8 .
To analyze the clinical impact of the statistically significant covariates, concentration profiles were simulated for a 250 mg single dose regimen. The results are shown in Figure 9 .
Creation of the NAR final model with forward method two
The Covariate model of NAR was created using two methods. In method two, forward method was conducted. The decrease in OFV of the forward method The control stream and the data file of method two are 501_naringenin.ctl and naringenin3-cn1.csv, respectively. The control stream and the results are shown in Table 5 .
Creation of the NAR final model with backward method two
All of the statistically significant covariates during univariate analysis were entered into the full model. In the backward deletion step, only SYAX led to an increase in OFV > 6.63 (P < 0.01). The control stream of the backward analysis covariate model is listed in Table 6 .
Diagnostics of the NAR final model with method two
The main informal diagnostic plots for the final model by basic goodness-of-fit plots of observed concentrations versus population and individually predicted concentrations, weighted residuals versus observed concentration, and weighted residuals versus time are shown in Figure 10 . Both the observed concentration data versus predicted concentration data of population and individual were scattered around the line of unity slope. The weighted residuals were uniformly spread around the zero line, and the weighted residuals fell into a normal distribution, which demonstrate that there was no bias in the base model.
Population parameters of the NAR final model with method two
The population parameters estimates of the final model with method two are listed in Table 7 . 
Visual predictive checking of the NAR final model with method two
The final model was checked by visual predictive checking, and the results are shown in Figure 11 .
Simulation of the NAR final model
To analyze the clinical impact of the statistically significant covariates, concentration profiles were simulated for a 250 mg single dose regimen, and the results are shown in Figure 12 .
DISCUSSION
PPK research is seldom carried out using TCM compounds or formulas, mainly because of sensitivity limitations. However, we used HPLC coupled with MS/ MS to detect the concentration of NAR in blood samples of patients after oral administration of one Qianggu capsule. This study is important for PPK research in TCM and will hopefully encourage further study within the field. One advantage of PPK is that the inclusion and exclusion criteria are quite different from those of classical pharmacokinetic studies. In fact, the exclusion criteria of classical pharmacokinetic studies are the inclusion criteria of PPK studies. In addition to the usual covariates selected in PPK studies, TCM symptoms and patterns can be considered as covariates and were added to our basic model for the first time. The results indicate that adoption of TCM patterns as covariates was necessary and meaningful. Therefore, as long as the ingredients are properly selected, PPK in TCM is feasible and its results can be implemented to assist in appropriate clinical utilization and side effect reduction of corresponding drugs. We also showed that the NONMEM approach can effectively estimate the distribution of parameters and their relationships with covariates in a population and provide a potential method of pharmacokinetic research in TCM. In recent years, various methods have been reported for the quantification of NAR in biological samples us-ing HPLC coupled with ultraviolet, fluorescence, or mass spectrometry to support preclinical and clinical studies. [4] [5] To fully evaluate the pharmacokinetics of NAR in plasma, several sensitive HPLC-MS/MS assay methods with appropriate sensitivity, selectivity, accuracy, and precision have been developed and validated. [5] [6] [7] Although the pharmacokinetic characteristics of purified NAR have been well investigated in animals, few studies involving humans have been performed. PPK can provide estimates of the sources and correlations of variability in drug concentrations among individuals and analyze complex factors that may influence the pharmacokinetic behavior of a drug. [8] [9] [10] [11] [12] [13] [14] However, PPK is seldom studied with TCM because the function of a single ingredient cannot represent that of the whole formula. Nevertheless, it can be concluded from the results of this study that among a dozen covariates, only hyperlipidemia was significantly correlated with NAR population parameters. NAR possesses a hypolipidemic effect, and could therefore have potential for clinical applications. As long as the ingredients are properly selected, PPK studies using TCM are not only feasible, but their results can be implemented to assist in appropriate clinical utilization and the side-effect reduction of corresponding drugs. Our population pharmacokinetic model effectively characterized the pharmacokinetic profile of NAR after administration of a single oral dose of Qianggu capsules in Chinese women with primary osteoporosis. Among the tested covariates, only SYAX, a pattern in TCM, was a significant factor. Figure 10 Observed data versus predicted data of final of method two A: the blue lines represent every possible opposite blood concentration point of the observations, the red lines represent the real average plots, and the black lines indicate the fitness; B: two different visual forms of the 95% confidence line (plot form and line form); C: every blue point indicates a prediction of possible blood concentration, and the red lines indicate the average of these blood concentrations. Almost all the points were around the average line, which means that the weighted residuals are almost the same; D: conditional weight residuals were around the zero line; E: the blue lines indicate every possible opposite blood concentration point of the observations, the red lines indicate the real average plots, and the black line indicates the fitness; F: the normal distribution of the conditional weighted residuals means that the main diagnostic plots for the base model were reliable. 
